Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)
Sponsor: Peking University Shenzhen Hospital
A PHASE1 clinical study on T-cell Acute Lymphoblastic Leukemia and T-cell Non-Hodgkin Lymphoma, this trial is ongoing. The trial is conducted by Peking University Shenzhen Hospital and has accumulated 7 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2024 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Oct 2021 — Jan 2024 [monthly]
Recruiting PHASE1
-
Apr 2021 — Oct 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Peking University Shenzhen Hospital
- iCAR Bio Therapeutics Ltd.
- iCell Gene Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .